Molecular Analytical Systems v. Ciphergen Biosystems, Inc.

186 Cal. App. 4th 696, 111 Cal. Rptr. 3d 876, 2010 Cal. App. LEXIS 1117
CourtCalifornia Court of Appeal
DecidedJuly 9, 2010
DocketH032845
StatusPublished
Cited by102 cases

This text of 186 Cal. App. 4th 696 (Molecular Analytical Systems v. Ciphergen Biosystems, Inc.) is published on Counsel Stack Legal Research, covering California Court of Appeal primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Molecular Analytical Systems v. Ciphergen Biosystems, Inc., 186 Cal. App. 4th 696, 111 Cal. Rptr. 3d 876, 2010 Cal. App. LEXIS 1117 (Cal. Ct. App. 2010).

Opinion

*701 Opinion

McADAMS, J.

This is an appeal from an order denying defendants’ motion to compel arbitration. Applying the law to the undisputed facts and exercising our independent judgment, we reverse the trial court’s ruling. As we explain below, plaintiff cannot avoid arbitrating its claims against the signatory defendant, because those claims are within the reach of the arbitration clause. And plaintiff cannot avoid arbitrating its claims against the nonsignatory defendant, because those claims are inextricably bound up with the obligations arising out of the agreement containing the arbitration clause.

BACKGROUND

The parties to this action are Molecular Analytical Systems (plaintiff or MAS) and Ciphergen Biosystems, Inc., and Bio-Rad Laboratories, Inc. (defendants).

The Contracts

Plaintiff is in a contractual relationship with defendant Ciphergen, arising from various contracts, including two that are at issue here: a “License Agreement” and a “Settlement Agreement,” both executed in 2003 following settlement of prior litigation. Plaintiff has no express contractual relationship with defendant Bio-Rad.

Both of the agreements at issue here contain arbitration provisions. Section 13.1 of the Settlement Agreement requires arbitration of “any dispute concerning the interpretation or enforcement of the terms of’ that agreement, the License Agreement, and other specified contracts. That requirement is qualified by Section 13.4 of the Settlement Agreement, which states: “Except as expressly set forth in Section 13.1, no dispute between the Parties need be submitted for binding arbitration, regardless of whether or not such dispute may arise out of or otherwise relate to” that agreement, the License Agreement, or the other specified contracts. The License Agreement incorporates those arbitration provisions by reference.

Plaintiff’s Complaint

In July 2007, plaintiff filed its complaint in this matter.

The complaint includes the following factual allegations: Plaintiff licensed certain technology rights to defendant Ciphergen in exchange for the payment *702 of royalties on total adjusted revenue, all as provided in the License Agreement, which is attached to the complaint as exhibit A. In 2006, “Ciphergen in substance assigned its rights under the License Agreement to Bio-Rad.” Ciphergen failed to secure plaintiff’s written consent to the assignment, as required by the License Agreement. “Ciphergen received $20 million in cash” from that transaction with Bio-Rad, which “constitutes revenue under the License Agreement.” But Ciphergen failed to pay royalties on that revenue. Plaintiff “has never entered into a commercial license agreement with Bio-Rad.” Nevertheless, in February 2007, plaintiff received a letter from Bio-Rad with a royalty check that did “not appear to be calculated upon Bio-Rad’s Adjusted Total Revenue as required by the License Agreement.”

The complaint contains nine causes of action, the first four naming Ciphergen, the next four naming Bio-Rad, and the last one naming both defendants. The four claims against Ciphergen alone are for breach of contract (first cause of action), breach of the implied covenant of good faith and fair dealing (second cause of action), fraud (third cause of action), and accounting (fourth cause of action). As against Bio-Rad, plaintiff asserts claims for interference with contract (fifth cause of action) and conversion (sixth cause of action). Alternatively, plaintiff posits the License Agreement as a contract between plaintiff and Bio-Rad, which Bio-Rad breached, thereby entitling plaintiff to an accounting (seventh and eighth causes of action). Finally, against both defendants, plaintiff seeks a declaration of contractual rights (ninth cause of action).

Defendants’ Motion to Compel Arbitration

In November 2007, both defendants moved for an order staying the court action and compelling arbitration.

In their memorandum of points and authorities in support of the motion, defendants sought arbitration of plaintiff’s claims against Ciphergen, asserting that they all fall within the scope of the arbitration provision. Defendants further argued that plaintiff’s “parallel claims against Bio-Rad must also be submitted to arbitration” based on the doctrine of equitable estoppel.

As evidentiary support for their motion, defendants submitted a copy of the Settlement Agreement, attached as an exhibit to the declaration of Ciphergen employee Eric Fung.

*703 Plaintiff opposed the motion, expressing disagreement with all of defendants’ arguments. 1 Plaintiff disputed the scope of the arbitration clause, arguing against arbitration of any of its tort or equity claims against either defendant. Additionally, plaintiff cited the lack of “any arbitration agreement with Bio-Rad” as a basis for refusing arbitration with both defendants, arguing first that plaintiff could not be compelled to arbitrate with Bio-Rad, because Bio-Rad is a nonsignatory, and further that plaintiff should not be compelled to arbitrate with Ciphergen, because of “the potential for conflicting results if MAS is compelled to arbitrate with Ciphergen.” (See Code Civ. Proc., § 1281.2, subd. (c).) 2

In December 2007, the court conducted a hearing on the motion. At defense counsel’s request, the court allowed posthearing supplemental briefing with submission thereafter.

In February 2008, the court issued its order denying defendants’ motion to compel arbitration. The order contains no explanation of the basis for the court’s ruling. Defendants thereafter requested a statement of decision, which the court denied as untimely. (See §§ 632, 1291.)

Appeal

Defendants brought this appeal.

In their opening brief, defendants make these arguments: all of plaintiff’s claims are within the scope of the arbitration agreement; Bio-Rad may enforce the arbitration clause; and section 1281.2(c) does not apply to this case.

In its respondent’s brief, plaintiff interposes these counterarguments: many of its claims are not subject to arbitration; defendants failed to show that Bio-Rad was a party to an arbitration agreement; nothing in the record supports application of the equitable estoppel doctrine; and section 1281.2(c) precludes arbitration.

In reply, defendants dispute all of plaintiff’s arguments.

*704 DISCUSSION

To establish the proper framework for our discussion, we first summarize the legal principles that inform our analysis. We then apply them to this case.

I. Legal Principles

A. Overview

“The purpose of arbitration is to have a simple, quick and efficient method to resolve controversies.” (New Linen Supply v. Eastern Environmental Controls, Inc.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Heritage Two LLC v. Bristol Farms CA2/1
California Court of Appeal, 2025
Galarsa v. Dolgen California
California Court of Appeal, 2025
Ford Motor Warranty Cases
California Supreme Court, 2025
Enmark v. KC Community Care
California Court of Appeal, 2024
Sandoval v. Parkwest Rehabilitation Center CA2/2
California Court of Appeal, 2024
Mabudian v. Beaver Medical Group CA4/1
California Court of Appeal, 2024
Rummell v. Lindsey CA4/1
California Court of Appeal, 2024
Wilson v. Hatch Bank
S.D. California, 2024
Davis v. Nissan North America, Inc.
California Court of Appeal, 2024
Oshodin v. Fire Insurance Exchange CA2/4
California Court of Appeal, 2024
Duran v. EmployBridge Holding Co.
California Court of Appeal, 2023
Duran v. EmployBridge Holding Co. CA5
California Court of Appeal, 2023
Tam v. KMS Automotive CA2/5
California Court of Appeal, 2023
Rocha v. U-Haul Co. of Cal.
California Court of Appeal, 2023
Flores v. C.H. Robinson Co., Inc. CA4/1
California Court of Appeal, 2022
Arcos v. Axiom Materials CA4/3
California Court of Appeal, 2021
Shechter v. Alta Hospitals System, LLC CA2/7
California Court of Appeal, 2021

Cite This Page — Counsel Stack

Bluebook (online)
186 Cal. App. 4th 696, 111 Cal. Rptr. 3d 876, 2010 Cal. App. LEXIS 1117, Counsel Stack Legal Research, https://law.counselstack.com/opinion/molecular-analytical-systems-v-ciphergen-biosystems-inc-calctapp-2010.